![Scott Coiante](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Coiante
Finanzdirektor/CFO bei
LEXICON PHARMACEUTICALS, INC.
Vermögen: 229 676 $ am 31.05.2026
Profil
Scott M.
Coiante is currently Chief Financial Officer & Senior Vice President at Lexicon Pharmaceuticals, Inc. since 2025.
Formerly, Mr. Coiante was Chief Financial Officer, Treasurer & Senior Vice President at Agile Therapeutics, Inc. from 2023 to 2024.
From 2019 to 2023, served as Chief Financial Officer & Senior Vice President at Aprea Therapeutics AB and as CFO, Secretary, Treasurer & Senior Vice President at Aprea Therapeutics, Inc. From 2010 to 2019, held the roles of CFO, Principal Accounting Officer & Senior Vice President at Agile Therapeutics, Inc. Between 2005 and 2010, was Treasurer, Chief Accounting Officer & VP-Finance at Medarex, Inc. Worked as Head-Financial Reporting at Ernst & Young LLP from 1989 to 2000.
Was a Member of the New Jersey Technology Council.
Education includes undergraduate studies at Villanova University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 06.03.2026 | 105’356 ( 0.02% ) | 229 676 $ | 31.05.2026 |
Aktive Positionen von Scott Coiante
| Unternehmen | Position | Beginn |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 02.01.2025 |
Ehemalige bekannte Positionen von Scott Coiante
| Unternehmen | Position | Ende |
|---|---|---|
| AGILE THERAPEUTICS, INC. | Finanzdirektor/CFO | 26.08.2024 |
| APREA THERAPEUTICS, INC. | Finanzdirektor/CFO | 30.01.2023 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Finanzdirektor/CFO | 01.01.2023 |
| AGILE THERAPEUTICS, INC. | Finanzdirektor/CFO | 05.08.2019 |
Medarex, Inc.
 Medarex, Inc. BiotechnologyHealth Technology Provides antibody and oncology drug development services | Finanzdirektor/CFO | 01.01.2005 |
Ausbildung von Scott Coiante
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
97
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Medarex, Inc.
Medarex, Inc. BiotechnologyHealth Technology Provides antibody and oncology drug development services | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Lexicon Pharmaceuticals, Inc.
 Lexicon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Agile Therapeutics, Inc.
 Agile Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures hormonal contraceptive products | Health Technology |
Villanova University
 Villanova University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Jersey Technology Council
 New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services Provides business development, education and advocacy services | Commercial Services |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
